Table 2 Sickle cell disease patients treated with hydroxyurea, characteristics
From: Sickle cell disease induces resistance to cutaneous carcinogenesis
Variable/Statistic | All patients (n = 187) |
|---|---|
Sex (% female) | 62.6 |
Age (years), median (range) | 31 (11–77) |
Geographic origin | |
-Sub-Saharan Africa (%) | 68.5 |
-French West Indies (%) | 23.5 |
-Mediterranean region | 6.4 |
-Madagascar | 1.6 |
SCD genotype | |
-SS (%) | 93 |
-Sb (%) | 3.7 |
-SC (%) | 2.6 |
-Sdpunjab (%) | 0.6 |
Hydroxyurea treatment | |
- Duration (years), median (range) | 6 (2–17) |
- Daily dose (mg), median (range) | 1100 (500–2000) |
Skin cancer reported | 0 |